Form 4: EcoR1 Capital Increases Stake in Zymeworks Inc. Through Multiple Open Market Purchases

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through a series of open market purchases between March 17 and March 19, 2025.

Summary

• EcoR1 Capital, LLC, along with Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P., have reported changes in their beneficial ownership of Zymeworks Inc. (ZYME) common stock.
• Between March 17 and March 19, 2025, EcoR1 Capital Fund Qualified, L.P. purchased a total of 229,403 shares of Zymeworks common stock through multiple transactions.
• The purchases were made at weighted average prices ranging from $12.2335 to $12.6524 and $12.6442 per share on March 17, 18 and 19 respectively.
• Following these transactions, EcoR1 Capital Fund Qualified, L.P. indirectly beneficially owns 17,030,604 shares of Zymeworks Inc.
• EcoR1 Capital, as the investment advisor to the Funds, and Oleg Nodelman, as the manager and controlling owner of EcoR1, may be deemed to indirectly beneficially own these shares.
• Both EcoR1 Capital and Oleg Nodelman disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The increased investment by EcoR1 Capital could be seen as a positive signal, but it's a routine transaction disclosure.

Positives

• EcoR1 Capital's increased investment in Zymeworks could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders and significant shareholders. This filing indicates increased investment by a major shareholder, which can influence market perception of the company.

Comparison to Industry Standards

• EcoR1 Capital's investment strategy often focuses on biotechnology companies with promising therapeutic pipelines.
• Similar investment firms like OrbiMed Advisors and RA Capital Management also actively manage their positions in publicly traded biotech companies.
• Monitoring these firms' investment activities can provide insights into industry trends and company-specific prospects.

Stakeholder Impact

• The increased stake by EcoR1 Capital could positively influence shareholder confidence.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Zymeworks, EcoR1 Capital, Oleg Nodelman, Beneficial Ownership, Stock Purchase, Form 4, ZYME